Ionis Pharmaceuticals (IONS) Common Equity (2009 - 2026)

Ionis Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $439.7 million for Q2 2026.

• In Q2 2026, Common Equity fell 30.39% year-over-year to $439.7 million; the TTM figure through Jun 2026 stood at $439.7 million (down 30.39% YoY), while the FY2025 annual figure was $489.1 million, down 16.87% from the prior year.
• Common Equity for Q2 2026 stood at $439.7 million, down from $491.4 million in the prior quarter.
• The five-year high for Common Equity was $709.6 million in Q1 2022, with the low at $263.7 million in Q2 2024.
• The 5-year median for Common Equity is $490.3 million (2025), against an average of $504.2 million.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 46.92% in 2023, then surged 139.56% in 2025.
• Ionis Pharmaceuticals' Common Equity stood at $572.9 million in 2022, then plunged by 32.5% to $386.7 million in 2023, then surged by 52.15% to $588.4 million in 2024, then declined by 16.87% to $489.1 million in 2025, then retreated by 10.09% to $439.7 million in 2026.
• Business Quant data shows IONS's Common Equity at $439.7 million in Q2 2026, $491.4 million in Q1 2026, and $489.1 million in Q4 2025.